Results 131 to 140 of about 9,301 (205)

Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians. [PDF]

J Family Med Prim Care
Aydemir C, Al Saidi R, Choi JS, Ahmed MH, Mital D.   +4 more
europepmc   +1 more source

Cellular determinants of raltegravir exposure [PDF]

, 2012
openaire   +2 more sources

Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed. [PDF]

Open Forum Infect Dis
Núñez I, Caro-Vega Y, MacDonald C, MacDonald C, Mosqueda-Gómez JL, Piñeirúa-Menéndez A, Matthews AA.   +6 more
europepmc   +1 more source

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

, 2010
Silvia Nozza, Laura Galli, Francesca Visco, Alessandro Soria, Filippo Canducci, Stefania Salpietro, Nicola Gianotti, Alba Bigoloni, Liviana Della Torre, Giuseppe Tambussi, Adriano Lazzarin, Antonella Castagna   +11 more
openalex   +1 more source

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen

, 2010
Constance Delaugerre, Isabelle Charreau, Joséphine Braun, Marie‐Laure Nere, Nathalie De Castro, Patrick Yéni, Jade Ghosn, J Aboulker, Jean‐Michel Molina, François Simon   +9 more
openalex   +1 more source

Salvage therapy with an Albuvirtide-based antiretroviral regimen for multi-drug resistant HIV and drug-resistant HBV with renal impairment: a case report. [PDF]

Virol J
He Y, Liao B, Liu Y, Cao Y, Li L, Cai W.
europepmc   +1 more source

PIN34 A CONTINUOUS-TIME ECONOMIC MODEL TO EVALUATE RALTEGRAVIR USE STRATEGIES IN TREATMENT-NAIVE HIV-1 PATIENTS IN PORTUGAL

, 2010
MA Chaudhary, EH Elbasha, Raul Pimenta da Cunha Pereira, RN Kumar   +3 more
openalex   +1 more source

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2. [PDF]

Viruses
Kiarie IW, Hoffka G, Laporte M, Leyssen P, Neyts J, Tőzsér J, Mahdi M.   +6 more
europepmc   +1 more source

Emergence of Bictegravir Resistance in a Treatment-Experienced PWH on Functional Monotherapy and Rapid Replacement by an Ancient Wild-Type Strain Following Transient Treatment Interruption. [PDF]

Viruses
Faré PB, Ziltener G, Bergadà Pijuan J, Abela IA, Hirsch BL, Huber M, Nemeth J, Günthard HF.   +7 more
europepmc   +1 more source

Raltegravir 800 mg once‐daily is efficacious in already virologically suppressed patients [PDF]

, 2012
Derek Ward, Robert Grant
openalex   +1 more source